ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
6096 articles about ACCESSWIRE
-
9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
3/21/2022
9 Meters Biopharma, Inc. announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the Maxim Group 2022 Virtual Growth Conference hosted by M-Vest on March 28 - 30, 2022. Maxim Group 2022 Virtual Growth Conference.
-
Welcome to IRLAB's Capital Markets Day 2022
3/18/2022
IRLAB will host a capital markets day on Tuesday March 22, 2022, in Stockholm to present the company's strategies, growth plan and key assets.
-
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2022
3/17/2022
Pharma-Bio Serv, Inc. announced that revenues for the quarter ended January 31, 2022 were approximately $5.0 million, an increase of approximately $0.5 million when compared to the same period last year.
-
Pressure BioSciences Updates Stakeholders with Solid Progress on Key 2022 Goals: UST Commercial Release, Major Revenue Increase, Continued Financial Position Improvement, and Planned Uplist to National Market
3/17/2022
Pressure BioSciences, Inc., a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, updated stakeholders on the Company's key 2022 goals.
-
SphingoTec and Rivaara Labs Close Exclusive Distribution Agreement for Point of Care Diagnostics in India
3/17/2022
The diagnostic company SphingoTec GmbH and Rivaara Labs Pvt Ltd. announced that they have entered into a multi-year distribution agreement for the commercialization of SphingoTec's point of care diagnostic solutions in the Indian subcontinent.
-
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
3/17/2022
RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, reported final data from its clinical trial of nasal spray, Sentinox, in SARS-CoV-2 infected patients.
-
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
3/17/2022
Moderna, Inc. announced that it has submitted a request to the U.S. Food and Drug Administration for an amendment to the emergency use authorization to allow for a fourth dose of its COVID-19 vaccine in adults 18 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.
-
Promore Pharma has Reached Recruitment Goal in Clinical Trial of Ensereptide
3/17/2022
Promore Pharma AB announces that the recruitment goal has been accomplished according to plan in the company's phase II study with the company's drug candidate ensereptide for the prevention of skin scarring.
-
Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update
3/17/2022
Viveve Medical, Inc., a medical technology company focused on women's intimate health, reported financial results for the year ended December 31, 2021.
-
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer
3/17/2022
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that its liquid biopsy focused subsidiary Inivata Limited has announced the publication of new data in support of its RaDaR™ liquid biopsy test in patients with early-stage non-small cell lung cancer.
-
Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
3/17/2022
Moderna, Inc. announced that Health Canada has approved the use of Moderna's mRNA COVID-19 vaccine, SPIKEVAX™, in a two-dose series of 50 µg per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 to11 years.
-
Abivax Reports 2021 Financial Results and Operations Update
3/16/2022
Abivax SA announces its 2021 annual financial results, as of December 31, 2021, and provides an update on the progress of its product pipeline.
-
NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
3/16/2022
NLS Pharmaceutics Ltd. announces positive interim top-line data from its Phase 2a clinical trial evaluating its lead product candidate, Quilience® (Mazindol ER), in the treatment of narcolepsy.
-
Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results
3/16/2022
Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, announced fiscal 2022 second quarter results for the period ending January 31, 2022.
-
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call
3/16/2022
Celcuity Inc. today announced that it will release its financial results for the fourth quarter and full year 2021 after the stock market close on Wednesday, March 23, 2022.
-
Vimian Group Acquires Veterinary Allergy Business in the UK
3/16/2022
Vimian Group has acquired the veterinary allergy division of AvactaGroup plc in the UK, to strengthen Vimian's position within veterinary allergy diagnostics and treatments in the UK. The business had revenues of GBP 1.6 million in 2021.
-
Biophytis will Participate in a Key Workshop on Functional Limitations for the Elderly
3/16/2022
Biophytis SA today announces its participation to a Virtual Workshopthe development of Function promoting therapies for the the elderly, organized by the National Institute on Aging based in Baltimore, USA.
-
Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
3/16/2022
Sonnet BioTherapeutics Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for SON-1010.
-
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
3/16/2022
Novamind Inc. is pleased to announce it has been selected by Mind Medicine, Inc. to host a phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder (GAD) in adults.
-
Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine
3/16/2022
Moderna, Inc. today announced an agreement with the Ministry of Health, Labour and Welfare of Japan (MHLW) to supply Japan with an additional 70 million doses of Moderna's COVID-19 booster vaccine or an updated booster vaccine candidate, if authorized, for anticipated delivery in the second half of 2022.